Paper · 41399682
Bile cell-free DNA shows benefit as a potential sample for somatic mutation detection of resectable cholangiocarcinoma.
Liu S and 10 others. ILIVER, 2025. Cited by 2 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Bile cell-free DNA shows benefit as a potential sample for somatic mutation detection of resectable cholangiocarcinoma. Papers, record 41399682. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41399682
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Bile cell-free DNA shows benefit as a potential sample for somatic mutation detection of resectable cholangiocarcinoma.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References35
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32,407,801 | Sputum Cell-Free DNA: Valued Surrogate Sample for Detection of EGFR Mutation in Patients with Advanced Lung Adenocarcinoma. | J Mol Diagn | 2020 | https://conductscience.org/library/papers/32407801 | PubMed |
| 2 | 34,454,680 | Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer. | Gynecol Oncol | 2021 | https://conductscience.org/library/papers/34454680 | PubMed |
| 3 | 32,606,456 | Cholangiocarcinoma 2020: the next horizon in mechanisms and management. | Nat Rev Gastroenterol Hepatol | 2020 | https://conductscience.org/library/papers/32606456 | PubMed |
| 4 | 33,919,036 | ctDNA-Based Liquid Biopsy of Cerebrospinal Fluid in Brain Cancer. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/33919036 | PubMed |
| 5 | 29,637,880 | Biomarkers for the Diagnosis of Cholangiocarcinoma: A Systematic Review. | Am J Trop Med Hyg | 2018 | https://conductscience.org/library/papers/29637880 | PubMed |
| 6 | 31,371,345 | Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy. | Cold Spring Harb Mol Case Stud | 2019 | https://conductscience.org/library/papers/31371345 | PubMed |
| 7 | 31,173,267 | Bile cell‑free DNA as a novel and powerful liquid biopsy for detecting somatic variants in biliary tract cancer. | Oncol Rep | 2019 | https://conductscience.org/library/papers/31173267 | PubMed |
| 8 | 33,579,226 | Clinically significant genomic alterations in the Chinese and Western patients with intrahepatic cholangiocarcinoma. | BMC Cancer | 2021 | https://conductscience.org/library/papers/33579226 | PubMed |
| 9 | 30,767,431 | Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC. | Cancer Med | 2019 | https://conductscience.org/library/papers/30767431 | PubMed |
| 10 | 34,040,697 | Liquid biopsy in cholangiocarcinoma: Current status and future perspectives. | World J Gastrointest Oncol | 2021 | https://conductscience.org/library/papers/34040697 | PubMed |
1 to 10 of 35
See all 35 referencesCited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,938,789 | Bile Cell-Free DNA as a Liquid Biopsy for Biliary Tract Malignancies: A Scoping Review. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42938789 | PubMed |
| 42,196,460 | Dynamic Time-Resolved Remodeling of the Immune Microenvironment After Resistance to BRAF/MEK Inhibitors in Melanoma: Mechanisms, Biomarkers, and Emerging Therapeutic Strategies. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42196460 | PubMed |
| 41,809,520 | Advancing hepatology through innovation and integration: iLIVER's vision for 2026. | ILIVER | 2026 | https://conductscience.org/library/papers/41809520 | PubMed |
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41399682
GET https://conductscience.org/api/papers/v1/41399682/references?page=2